Emergent BioSolutions (EBS) has secured a $51.9M contract modification award to deliver CNJ-016 to the Administration for Strategic Preparedness and Response (A ...

About an hour after the closing bell, shares of Emergent were trading 6.4% higher, at $7.31. The company's shares ended the day's regular session at $6.87, a gain of 3.7%.

Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment ...

Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous ...

Investing.com -- Emergent BioSolutions Inc (NYSE: EBS) stock rose 6.3% after the company announced a contract modification to deliver additional doses of its smallpox vaccination complication ...

A little less than a year after topping up its medical countermeasure contracts with Emergent BioSolutions, the federal ...

Emergent BioSolutions Inc. announced that it will be included in the Russell 3000® Index effective June 27, 2025, as part of the annual reconstitution of the Russell U.S. stock indexes.

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the Company will be added to the broad-market Russell 3000® Index, effective after the ...

Emergent BioSolutions Inc. announced the award of a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR) to supply its Botulism Antitoxin ...

South Korea has developed the world's first recombinant protein-based anthrax vaccine, a major step toward self-sufficiency ...

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in CanadaLONDON and GAITHERSBURG, Md., March 20, 2025 ...